Tags

Type your tag names separated by a space and hit enter

Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov. 2020 Jul; 10(7):OF8.CD

Abstract

Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19. Preliminary data from randomized trials are less clear-cut.

Pub Type(s)

News

Language

eng

PubMed ID

32371479

Citation

"Cytokine Storm Drugs Move From CAR T to COVID-19." Cancer Discovery, vol. 10, no. 7, 2020, pp. OF8.
Cytokine Storm Drugs Move from CAR T to COVID-19. Cancer Discov. 2020;10(7):OF8.
(2020). Cytokine Storm Drugs Move from CAR T to COVID-19. Cancer Discovery, 10(7), OF8. https://doi.org/10.1158/2159-8290.CD-ND2020-008
Cytokine Storm Drugs Move From CAR T to COVID-19. Cancer Discov. 2020;10(7):OF8. PubMed PMID: 32371479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytokine Storm Drugs Move from CAR T to COVID-19. Y1 - 2020/05/05/ PY - 2020/5/7/pubmed PY - 2020/7/21/medline PY - 2020/5/7/entrez SP - OF8 EP - OF8 JF - Cancer discovery JO - Cancer Discov VL - 10 IS - 7 N2 - Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19. Preliminary data from randomized trials are less clear-cut. SN - 2159-8290 UR - https://www.unboundmedicine.com/medline/citation/32371479/Cytokine_Storm_Drugs_Move_from_CAR_T_to_COVID_19_ L2 - http://cancerdiscovery.aacrjournals.org/cgi/pmidlookup?view=long&pmid=32371479 DB - PRIME DP - Unbound Medicine ER -